Financial Performance & Acquisition - Alkermes' commercial business generated revenues exceeding $1.45 billion in 2025, demonstrating strong cash flow and profitability[5] - The planned acquisition of Avadel is expected to augment revenue growth and enhance profitability in 2026[5, 46] - LUMRYZ has generated over $390 million in net revenues since its launch as of September 30, 2025[49] Alixorexton Development Program - Alixorexton has blockbuster potential in narcolepsy and idiopathic hypersomnia and was granted FDA Breakthrough Therapy designation in NT1, with Phase 3 initiation planned for Q1 2026[5] - Phase 2 Vibrance-1 study showed statistically significant improvements in mean sleep latency and excessive daytime sleepiness, with clinically meaningful improvements in weekly cataplexy rates in NT1 patients[16] - Phase 2 Vibrance-2 study demonstrated clinically meaningful improvements in wakefulness and excessive daytime sleepiness in NT2 patients[19] Market Opportunity & Pipeline Expansion - The orexin 2 receptor agonist class represents a potential multi-billion dollar market opportunity in narcolepsy and idiopathic hypersomnia[9] - The oxybate market for narcolepsy and idiopathic hypersomnia generated over $1.8 billion in revenues in 2024[11] - Approximately 80,000 narcolepsy patients are treated, with 80% reporting residual symptoms[11] - Alkermes is planning a Phase 2 study of ALKS 4510 in 2026 for fatigue associated with multiple sclerosis and Parkinson's Disease, with a prevalence of approximately 1 million patients each in the US[40]

Extraordinary Care That Changes Lives Option Care Health, Inc. 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 © 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 1 Disclaimers Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estim ...

J.P. Morgan Healthcare Conference January 13, 2026 Catherine Owen Adams Chief Executive Officer 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," ...

Financial Performance & Goals - Royalty Pharma's 2025 Portfolio Receipts guidance midpoint is $3225 million, representing approximately 15% growth[7] - The company's Return on Invested Capital was 157% and Return on Invested Equity was 229% in Q3 2025 LTM (Last Twelve Months)[7] - The company aims for Portfolio Receipts of over $47 billion by 2030, implying a CAGR of 10% or more from 2020[18] - The company projects approximately $30 billion of capital deployment capacity from H2 2025 to 2030[73] Capital Allocation & Investment - The company announced $47 billion in new royalty deals in 2025, with $26 billion in Capital Deployment[7] - The company repurchased $12 billion of shares and increased dividends by a mid-single digit percentage[7] - The company deployed approximately 65% of capital on approved products since 2012[45] - The company announced four synthetic royalty deals in 2025, totaling $2075 million in announced value[36] Portfolio & Pipeline - The company's portfolio includes therapies like Tremfya, which received FDA and EC approval for Crohn's disease and EC approval for ulcerative colitis[59] - The company anticipates peak royalties ranging from approximately $180 million to $340 million from daraxonrasib for pancreatic cancer[62, 64] - The company expects peak royalties of over $400 million from frexalimab for multiple sclerosis[62, 64]

McKesson Corporation J.P. Morgan Healthcare Conference January 13, 2026 Brian Tyler Chief Executive Officer 1 © 2026 McKesson Corporation. All rights reserved. Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," ...

JANUARY 2026 Beyond Innovation to Impact: Building the Premier Endocrinology Business J.P. Morgan Healthcare Conference Angela Living with Acromegaly Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forw ...

J.P. Morgan 44th Healthcare Conference Prahlad Singh Chief Executive Officer January 13, 2026 Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to the Company's customers and end-markets, plans concerning business development oppo ...

Strategy and Focus - Novo Nordisk focuses on innovation-driven opportunities within core therapeutic areas[9, 13] - The company's strategy centers on leading in Obesity, Diabetes, and related comorbidities[10, 14] Market Needs and Opportunities - There is a significant unmet need within Diabetes, with >550 million people living with T1D or T2D and ~7% of diabetes prescriptions are for a GLP-1[11, 15] - A significant unmet need exists within Obesity, with >900 million people living with obesity and only ~2% are treated with branded Anti-Obesity Medications (AOMs)[11, 15] - Select related comorbidities include >800 million people living with MASH, 250 million with CVD, and >500 million with CKD[11, 15] Key Priorities for 2026 - Accelerate commercial execution, including the launch of Wegovy® pill in the US and roll out of semaglutide 7.2 mg, and expand Direct-to-Patient and cash channels[18] - Reinforce organizational focus through organizational set-up & culture coming out of transformation and resource allocation towards growth opportunities[18] - Strengthen the R&D pipeline by progressing late-stage pipeline and bringing several new obesity & diabetes assets into the clinic[18] Forward-Looking Statements - The company's statements may contain forward-looking statements relating to operating, financial, and sustainability performance[3] - These statements are based on current plans, estimates, opinions, views, and projections, but actual results may differ materially due to risks, uncertainties, and assumptions[4]

Kymera's Strategy and Pipeline - Kymera is focused on developing oral degrader medicines with biologics-like activity to transform immunology treatments[7, 16] - The company's pipeline includes KT-621 (STAT6 degrader), KT-579 (IRF5 degrader), and KT-485 (IRAK4 degrader), targeting various immunological diseases[27] - Kymera expects to report Phase 2b AD study data by mid-2027 and Phase 2b asthma study data in late-2027 for KT-621[27, 92] - A Phase 1 healthy volunteer trial for KT-579 is expected to initiate in Q1 2026, with data reported in 2H 2026[27, 92] - Sanofi plans to advance KT-485 into a Phase 1 clinical trial in 2026[14, 91] KT-621 Clinical Data and Market Opportunity - KT-621 has shown deep STAT6 degradation (>95%) in healthy volunteers and AD patients[44] - In the BroADen Phase 1b AD trial, KT-621 achieved significant reductions in EASI score (-63%), Total SCORAD (-48%), Peak Pruritus NRS (-40%), and SCORAD-Itch (-44%)[53, 54, 57] - KT-621 also demonstrated improvements in patient-reported outcomes, with 61% DLQI responders and 75% POEM responders[60] - KT-621 achieved a 56% median FeNO reduction in AD patients with comorbid asthma[71] - The potential patient impact for STAT6 inhibition in Type 2 inflammation is estimated to be >140 million, representing a >$20 billion market[35] Financial Position - Kymera is capitalized with $1.6 billion in cash, providing a runway into 2029[14]

Agilent Technologies Padraig McDonnell, President & CEO J.P. Morgan Healthcare Conference January 13, 2026 2026 J.P. Morgan Healthcare Conference Safe harbor This presentation contains forward-looking statements (including, without limitation, statements on Agilent's (the "company" or "our") strategy, priorities, growth and growth opportunities, productivity, reinvestment, customer focus, evolving product mix, work environment and innovation plans; the effects of the Ignite Operating System; the size and gr ...